GSI Group Inc. — FY2013 Form 10-K
Entity and period: The supplied filing is for GSI Group Inc. for the fiscal year ended December 31, 2013, and was filed March 13, 2014. It is an annual report, not a standalone fourth-quarter filing. The request identifies Novanta Inc., but the filing itself names GSI Group Inc.; verify the issuer identity and any successor-company relationship before attributing these results.
Business context
GSI designed and manufactured photonics, laser, medical visualization and informatics, and precision-motion products, primarily for OEMs. Following a fourth-quarter segment realignment, it reported Laser Products, Medical Technologies, and Precision Motion. The January 2013 NDS acquisition materially expanded Medical Technologies; the company also sold its Semiconductor Systems business in 2013.
Key financial metrics
Amounts below are in U.S. dollars; annual results are continuing operations unless otherwise noted.
| Metric | FY2013 | FY2012 |
|---|---|---|
| Sales | $341.6 million | $271.5 million |
| Gross profit / margin | $139.4 million / 40.8% | $114.5 million / 42.2% |
| Operating income / margin | $17.7 million / 5.2% | $15.0 million / 5.5% |
| Income from continuing operations | $8.9 million | $22.5 million |
| Diluted EPS from continuing operations | $0.26 | $0.66 |
| Net income attributable to GSI | $7.3 million | $19.5 million |
| Cash provided by operating activities | $49.2 million | $28.4 million |
| Cash and cash equivalents, year-end | $61.0 million | $65.8 million |
| Total debt, year-end | $71.5 million | $50.0 million |
Current assets were $199.8 million versus current liabilities of $60.1 million at year-end 2013. Cash exceeded debt by approximately $10.5 million. The company reported $46.0 million of available revolving-credit capacity at year-end. Operating cash flow included substantial tax refunds; the cash-flow statement reports $12.6 million in income-tax refunds received.
In the fourth quarter of 2013, sales were $87.7 million, operating income was $6.7 million, income from continuing operations was $4.4 million, and diluted EPS from continuing operations was $0.13. Fourth-quarter 2012 sales were $66.4 million and operating income was $3.3 million; reported continuing-operations income of $14.9 million was boosted by a $15.3 million deferred-tax valuation-allowance release.
Material changes versus prior year
- Annual sales increased 25.8%, but $68.4 million of NDS sales accounted for nearly all of the increase. Excluding NDS and foreign-exchange effects, organic sales growth was 1.5%.
- Gross margin declined 1.4 percentage points. Management cited product mix, NDS acquisition-related amortization and inventory fair-value adjustments, and higher costs associated with new sealed CO2 laser products.
- Operating income rose 17.9%, while continuing-operations income and EPS fell substantially. The 2012 result benefited from the $15.3 million tax valuation-allowance release; 2013 recorded a $5.7 million tax expense.
- Medical Technologies sales rose to $90.3 million from $25.9 million, principally because NDS contributed $68.4 million. Excluding NDS, segment sales declined 15.5%; segment gross margin fell to 39.7% from 50.7%.
- Laser Products sales increased 2.7%; Precision Motion sales increased 1.3%. Precision Motion continued to face cyclical electronics-market exposure, despite a short-term rebound in air-bearing spindle demand.
- Operating cash flow increased to $49.2 million, helped by tax refunds, improved operating results, and lower discontinued-operation losses. Investing cash flow was negative $73.0 million, primarily reflecting the $80.8 million NDS purchase.
Outlook, risks, contingencies and unusual items
- Management said expected operating cash flows should cover operating and capital needs for at least the next 12 months. It expected 2014 capital expenditures of $5–$6 million; no numerical revenue or earnings guidance was provided.
- On February 18, 2014, GSI agreed to acquire JADAK for $93.5 million cash, subject to customary closing conditions and then expected to close in March 2014. The company anticipated funding the acquisition with cash and credit-facility borrowings; it expected to borrow an additional $68 million under its facilities.
- A January 2014 letter of intent proposed selling the scientific lasers business for $7.5 million cash, plus up to $3.0 million contingent consideration. Management expected a pretax loss of $1.5–$2.5 million and expected the business to be classified as held for sale and discontinued in first-quarter 2014. The business generated about $25 million of 2013 revenue.
- A February 2014 credit amendment increased the revolving facility commitment from $75 million to $175 million and raised the maximum permitted consolidated leverage ratio from 2.75 to 3.00. At December 31, 2013, reported leverage was 1.41 against the amended 3.00 limit, and fixed-charge coverage was 4.16 against a 1.50 minimum.
- Key disclosed risks include cyclical customer capital spending, weak electronics and scientific markets, foreign-exchange exposure, reliance on certain single-source suppliers, product-development and integration risks, regulatory requirements for medical and laser products, and debt covenants. A 100-basis-point rate increase was estimated to add about $0.7 million to annual pretax interest expense.
- Gross unrecognized tax benefits were $7.1 million; up to $2.1 million could be recorded as a benefit over the next 12 months if statutes of limitation expire. The U.K. and Japan defined-benefit plans were underfunded by approximately $1.7 million and $0.8 million, respectively.
- The Paris Court of Appeals affirmed dismissal of a receiver’s claim against GSI Group Ltd. and a German subsidiary on March 4, 2014. The company said ordinary-course claims were not expected to have a material adverse effect, while noting outcomes cannot be assured.
- The 2013 financial statements received an unqualified audit opinion, and management and the auditor concluded internal control over financial reporting was effective as of year-end.
Most important facts to verify
- Confirm that this GSI Group Inc. filing is the intended issuer for the Novanta Inc. request, including the relevant corporate name or successor relationship.
- Separate acquisition-driven growth from underlying performance: verify NDS contribution, organic growth, and the acquired business’s 2013 pretax loss of $3.4 million.
- Review the drivers and persistence of the gross-margin decline, especially Medical Technologies’ lower margin and acquisition-related charges.
- Assess post-year-end financing and liquidity after the JADAK purchase, including actual borrowing, covenant headroom, and integration results.
- Track completion and proceeds of the proposed scientific-lasers divestiture, including contingent consideration and the final loss.
- Distinguish recurring earnings and cash generation from the prior-year tax benefit and 2013 tax refunds; review tax attributes and unresolved tax positions.